dc.creator | Karathanos C., Chatzis D., Latzios P., Papakostas I., Goumas K., Giannoukas A.D., on behalf of the SeVEN EXT Collaborators | en |
dc.date.accessioned | 2023-01-31T08:31:39Z | |
dc.date.available | 2023-01-31T08:31:39Z | |
dc.date.issued | 2021 | |
dc.identifier | 10.1177/0268355520947300 | |
dc.identifier.issn | 02683555 | |
dc.identifier.uri | http://hdl.handle.net/11615/74446 | |
dc.description.abstract | Background: To assess the treatment of superficial vein thrombosis (SVT) with intermediate dose of tinzaparin in a setting of real world practice. Methods: Prospective observational study of consecutive patients treated by vascular physicians in the private sector with tinzaparin (131 IU/Kg) once daily. Treatment duration was at the treating physician’s discretion. The outcomes of the study were symptomatic venous thromboembolism, extension of thrombus and bleeding complications. Results: 660 patients were included and followed up for at least 3 months. Median duration of treatment was 30 days (14–120). History of prior deep vein thrombosis (HR 2.77; 95% CI= 1.18–6.49; p = 0.018) and current SVT above the knee (HR1.84; 95% CI = 1.33–3.53; p = 0.0002) were associated with prolonged treatment duration. Primary efficacy outcomes occurred in 20 (3%) patients. The median time to the event was 24 (6–92) days and was not related to treatment duration. Conclusions: Tinzaparin at intermediate dose is an effective and safe treatment for SVT. © The Author(s) 2021. | en |
dc.language.iso | en | en |
dc.source | Phlebology | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85098947384&doi=10.1177%2f0268355520947300&partnerID=40&md5=99e6fcebcc388b3b5defb96db46b98d9 | |
dc.subject | tinzaparin | en |
dc.subject | anticoagulant agent | en |
dc.subject | low molecular weight heparin | en |
dc.subject | tinzaparin | en |
dc.subject | adult | en |
dc.subject | aged | en |
dc.subject | Article | en |
dc.subject | cohort analysis | en |
dc.subject | deep vein thrombosis | en |
dc.subject | disease association | en |
dc.subject | drug efficacy | en |
dc.subject | drug safety | en |
dc.subject | epistaxis | en |
dc.subject | female | en |
dc.subject | human | en |
dc.subject | lung embolism | en |
dc.subject | major clinical study | en |
dc.subject | male | en |
dc.subject | medical history | en |
dc.subject | observational study | en |
dc.subject | postthrombosis syndrome | en |
dc.subject | prospective study | en |
dc.subject | recurrent disease | en |
dc.subject | superficial thrombophlebitis | en |
dc.subject | treatment duration | en |
dc.subject | venous thromboembolism | en |
dc.subject | thrombosis | en |
dc.subject | treatment outcome | en |
dc.subject | vein thrombosis | en |
dc.subject | Anticoagulants | en |
dc.subject | Cohort Studies | en |
dc.subject | Heparin, Low-Molecular-Weight | en |
dc.subject | Humans | en |
dc.subject | Thrombosis | en |
dc.subject | Tinzaparin | en |
dc.subject | Treatment Outcome | en |
dc.subject | Venous Thrombosis | en |
dc.subject | SAGE Publications Ltd | en |
dc.title | Treatment of superficial vein thrombosis with intermediate dose of tinzaparin: A real word cohort study – The SeVEN EXTension study | en |
dc.type | journalArticle | en |